Enveric Biosciences, Inc.
About Enveric Biosciences, Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $39.9M
- Net income
- -$8.8M
- Total assets
- $5.1M
- Market cap
- $6.6M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $6.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 24, 1995
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Enveric Biosciences, Inc..